OR WAIT null SECS
Kangstem Biotech has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD.
Korean-based biotechnology company, Kangstem Biotech, has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD-the stem cell therapeutic product targeting atopic dermatitis, the company announced on Oct. 1, 2018.
Through this partnership, Kangstem gains access to MaSTherCell’s cell therapy manufacturing expertise, capabilities, and new commercial Agility-by-Design facility. Furthermore, Kangstem’s expansion into other continents may be facilitated by MaSTherCell’s global reach and facilities.
“The European clinical trial of Furestem-AD will be a milestone for our company. We believe that MaSTherCell's expertise and experience will be the key to enable it,” said Tae Wha Lee, CEO of Kangstem, in a press release.
“Kangstem’s allogeneic human umbilical cord blood-derived stem cell-based project fits perfectly in MaSTherCell’s long-term strategy to provide services across all segments of the cell therapy field,” said Romain de Rauville, business development manager and head of Europe at MaSTherCell. “Being selected by a Korean cell therapy company really portrays MaSTherCell’s expertise and agility in assisting our partners with their globalization. Kangstem’s efficient manufacturing process will further increase MaSTherCell’s expertise and skills to broaden the impact of both companies on the cell therapy field.”